Tavokinogene Telseplasmid With Electroporation, Pembrolizumab, and Epacadostat in Treating Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck

Conditions:   Metastatic Head and Neck Squamous Cell Carcinoma;   Recurrent Head and Neck Squamous Cell Carcinoma;   Unresectable Head and Neck Squamous Cell Carcinoma
Interventions:   Device: Electroporation;   Drug: Epacadostat;   Drug: Pembrolizumab
Sponsors:   University of California, San Francisco;   National Cancer Institute (NCI)
Not yet recruiting

http://bit.ly/2HM4Y2q